7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Lorget F et al. | Lactoferrin reduces in vitro osteoclast differentiation and resorbing activity. | 2002 | Biochem. Biophys. Res. Commun. | pmid:12163011 |
| Ulrich-Vinther M et al. | Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. | 2002 | J Bone Joint Surg Am | pmid:12177271 |
| Ohmori H et al. | Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. | 2002 | J. Hum. Genet. | pmid:12181640 |
| Armstrong AP et al. | A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. | 2002 | J. Biol. Chem. | pmid:12185073 |
| Schoppet M et al. | RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. | 2002 | Arterioscler. Thromb. Vasc. Biol. | pmid:11950689 |
| Hasegawa T et al. | Human periodontal ligament cells derived from deciduous teeth induce osteoclastogenesis in vitro. | 2002 | Tissue Cell | pmid:11989970 |
| Zhang J et al. | Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. | 2002 | J. Bone Miner. Res. | pmid:12096839 |
| Treuheit MJ et al. | Inverse relationship of protein concentration and aggregation. | 2002 | Pharm. Res. | pmid:12033388 |
| Lossdörfer S et al. | Immunohistochemical localization of receptor activator of nuclear factor kappaB (RANK) and its ligand (RANKL) in human deciduous teeth. | 2002 | Calcif. Tissue Int. | pmid:12043011 |
| Zhang J et al. | PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. | 2002 | FEBS Lett. | pmid:12067713 |
| Wynne F et al. | Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish population. | 2002 | Calcif. Tissue Int. | pmid:12073153 |
| Crotti TN et al. | Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. | 2002 | Ann. Rheum. Dis. | pmid:12429533 |
| Hofbauer LC and Schoppet M | Osteoprotegerin deficiency and juvenile Paget's disease. | 2002 | N. Engl. J. Med. | pmid:12432053 |
| Jono S et al. | Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. | 2002 | Circulation | pmid:12208791 |
| Sedger LM et al. | Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. | 2002 | Eur. J. Immunol. | pmid:12209637 |
| Hofbauer LC et al. | Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. | 2002 | J. Cell. Biochem. | pmid:12210731 |
| Kondo H et al. | Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. | 2002 | J. Bone Miner. Res. | pmid:12211438 |
| Stajszczyk M | [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism]. | 2002 | Pol. Arch. Med. Wewn. | pmid:12600190 |
| Fahrleitner A et al. | Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status. | 2002 | Wien. Klin. Wochenschr. | pmid:12602117 |
| Takayanagi H | [Cross-talk between immune and skeletal systems]. | 2002 | Nippon Rinsho | pmid:12510352 |
| Shimizu-Ishiura M et al. | Osteoprotegerin administration reduces femural bone loss in ovariectomized mice via impairment of osteoclast structure and function. | 2002 | J Electron Microsc (Tokyo) | pmid:12455916 |
| Mochizuki S et al. | Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. | 2002 | J. Bone Miner. Metab. | pmid:11810411 |
| Avbersek-Luznik I et al. | Increased levels of osteoprotegerin in hemodialysis patients. | 2002 | Clin. Chem. Lab. Med. | pmid:12476941 |
| Childs LM et al. | In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. | 2002 | J. Bone Miner. Res. | pmid:11811549 |
| Buckley KA et al. | Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-kappa B ligand. | 2002 | Bone | pmid:12477572 |
| Saidenberg Kermanac'h N et al. | Osteoprotegerin and inflammation. | 2002 Apr-Jun | Eur. Cytokine Netw. | pmid:12101070 |
| Jung K et al. | Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. | 2002 Jul-Sep | Int. J. Biol. Markers | pmid:12408468 |
| Amizuka N et al. | Defective bone remodelling in osteoprotegerin-deficient mice. | 2003 | J Electron Microsc (Tokyo) | pmid:14756238 |
| Kawana F and Sasaki T | Osteoclast differentiation and characteristic trabecular bone formation during growth plate destruction in osteoprotegerin-deficient mice. | 2003 | J Electron Microsc (Tokyo) | pmid:14756239 |
| Cheng X et al. | The TNF receptor superfamily: role in immune inflammation and bone formation. | 2003 | Immunol. Res. | pmid:12857975 |
| Shin MM et al. | High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors. | 2003 | Exp. Mol. Med. | pmid:12858015 |
| Gehrke T et al. | Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. | 2003 | Scand. J. Rheumatol. | pmid:14690142 |
| Glossop JR et al. | No association of polymorphisms in the tumor necrosis factor receptor I and receptor II genes with disease severity in rheumatoid arthritis. | 2003 | J. Rheumatol. | pmid:12858434 |
| Hampson G et al. | Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial. | 2003 | Osteoporos Int | pmid:12904840 |
| Stolina M et al. | Regulatory effects of osteoprotegerin on cellular and humoral immune responses. | 2003 | Clin. Immunol. | pmid:14697750 |
| Misra M et al. | Serum osteoprotegerin in adolescent girls with anorexia nervosa. | 2003 | J. Clin. Endocrinol. Metab. | pmid:12915674 |
| Lonergan M et al. | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. | 2003 | J. Clin. Endocrinol. Metab. | pmid:12915677 |
| Kapczuk K et al. | [Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects]. | 2003 | Ginekol. Pol. | pmid:12916277 |
| Liu JZ et al. | [Co-expression of human bone morphogenetic protein-2 and osteoprotegerin in myoblast C2C12]. | 2003 | Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi | pmid:12916296 |
| Bendre MS et al. | Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. | 2003 | Bone | pmid:12919697 |
| Tabb MM et al. | Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. | 2003 | J. Biol. Chem. | pmid:12920130 |
| Park HR et al. | Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. | 2003 | J. Korean Med. Sci. | pmid:12923331 |
| Paloneva J et al. | DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. | 2003 | J. Exp. Med. | pmid:12925681 |
| Fukushima H et al. | Expression and role of RANKL in periodontal ligament cells during physiological root-resorption in human deciduous teeth. | 2003 | Eur. J. Oral Sci. | pmid:12887401 |
| Ito R et al. | Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. | 2003 | Virchows Arch. | pmid:12838418 |
| Zhang Z et al. | Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. | 2003 | J. Immunol. | pmid:14500659 |
| Ueno Y et al. | In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. | 2003 | J. Cell. Biochem. | pmid:14505343 |
| Kaneyama K et al. | Osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluid from patients with temporomandibular disorders. | 2003 | Int J Oral Maxillofac Surg | pmid:14505625 |
| Miyahira Y et al. | Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination. | 2003 | J. Immunol. | pmid:14662831 |
| Seidlova-Wuttke D et al. | Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. | 2003 | Eur. J. Endocrinol. | pmid:14514351 |
| Hortobagyi GN | Novel approaches to the management of bone metastases. | 2003 | Semin. Oncol. | pmid:14613037 |
| Voskaridou E et al. | Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. | 2003 | Br. J. Haematol. | pmid:14616979 |
| Uemura H et al. | Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover. | 2003 | Bone | pmid:14623063 |
| Novack DV | TSH, the bone suppressing hormone. | 2003 | Cell | pmid:14567908 |
| Grigorie D et al. | Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. | 2003 | Rom J Intern Med | pmid:15526523 |
| Nagata N et al. | Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. | 2003 | Bone | pmid:14555278 |
| Grimaud E et al. | Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. | 2003 | Am. J. Pathol. | pmid:14578201 |
| Bord S et al. | The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. | 2003 | Bone | pmid:12633785 |
| Coen G et al. | Serum leptin in dialysis renal osteodystrophy. | 2003 | Am. J. Kidney Dis. | pmid:14582047 |
| Garber K | Why it hurts: researchers seek mechanisms of cancer pain. | 2003 | J. Natl. Cancer Inst. | pmid:12783923 |
| Chagraoui H et al. | Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. | 2003 | Exp. Hematol. | pmid:14585373 |
| Liu B et al. | Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. | 2003 | J. Oral Pathol. Med. | pmid:12787044 |
| Eaton CL and Coleman RE | Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. | 2003 | Cancer Treat. Rev. | pmid:12787713 |
| Fahrleitner-Pammer A et al. | Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. | 2003 | Wien. Klin. Wochenschr. | pmid:12793029 |
| Dovio A et al. | Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002. | 2003 | Clin. Cancer Res. | pmid:12796409 |
| Flick LM et al. | Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. | 2003 | J. Orthop. Res. | pmid:12798068 |
| Khapli SM et al. | IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. | 2003 | J. Immunol. | pmid:12816992 |
| Kawase Y et al. | Bone malformations in interleukin-18 transgenic mice. | 2003 | J. Bone Miner. Res. | pmid:12817749 |
| Kikuchi T et al. | Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. | 2003 | J. Dent. Res. | pmid:12821717 |
| D'Elia HF et al. | Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. | 2003 | Arthritis Res. Ther. | pmid:12823855 |
| Knudsen ST et al. | Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. | 2003 | Eur. J. Endocrinol. | pmid:12824864 |
| Fox SW et al. | The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. | 2003 | J. Immunol. | pmid:12646633 |
| Moreno JL et al. | IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. | 2003 | Blood | pmid:12689929 |
| Dovio A et al. | Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. | 2003 | J. Endocrinol. | pmid:12697042 |
| Nakano M et al. | Inhibitory effect of titanium particles on osteoclast formation generated by treatment of mouse bone marrow cells with PGE2. | 2003 | Oral Dis | pmid:12657033 |
| Ra JS et al. | Osteoprotegerin inhibits proliferation of myeloid progenitor cells. | 2003 | J. Hematother. Stem Cell Res. | pmid:12662434 |
| Szalay F et al. | High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. | 2003 | J. Hepatol. | pmid:12663228 |
| Okada Y et al. | Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. | 2003 | J. Biol. Chem. | pmid:12665515 |
| Bell NH | RANK ligand and the regulation of skeletal remodeling. | 2003 | J. Clin. Invest. | pmid:12697730 |
| Eghbali-Fatourechi G et al. | Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. | 2003 | J. Clin. Invest. | pmid:12697741 |
| Enomoto H et al. | Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. | 2003 | J. Biol. Chem. | pmid:12697767 |
| Nakashima T et al. | RANKL and RANK as novel therapeutic targets for arthritis. | 2003 | Curr Opin Rheumatol | pmid:12707582 |
| Johnson-Pais TL et al. | Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. | 2003 | Int. J. Cancer | pmid:12673693 |
| Zaidi M et al. | Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. | 2003 | J. Bone Miner. Res. | pmid:12674320 |
| Tanaka S et al. | Signal transduction pathways regulating osteoclast differentiation and function. | 2003 | J. Bone Miner. Metab. | pmid:12720046 |
| Valleala H et al. | Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. | 2003 | Eur. J. Endocrinol. | pmid:12720535 |
| Lipton A | Bisphosphonates and metastatic breast carcinoma. | 2003 | Cancer | pmid:12548585 |
| Demers LM | Bone markers in the management of patients with skeletal metastases. | 2003 | Cancer | pmid:12548589 |
| Body JJ et al. | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. | 2003 | Cancer | pmid:12548591 |
| Xing L et al. | Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. | 2003 | J. Bone Miner. Res. | pmid:12568403 |
| Cao J et al. | Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. | 2003 | J. Bone Miner. Res. | pmid:12568404 |
| Johnson-Pais TL et al. | Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. | 2003 | J. Bone Miner. Res. | pmid:12568416 |
| Clohisy JC et al. | RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. | 2003 | J. Orthop. Res. | pmid:12568950 |
| Fahrleitner A et al. | Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. | 2003 | Bone | pmid:12584041 |
| Lanzi R et al. | GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. | 2003 | Eur. J. Endocrinol. | pmid:12590637 |
| Shipman CM and Croucher PI | Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. | 2003 | Cancer Res. | pmid:12615702 |
| Hamzei M et al. | Osteoclast stimulating and differentiating factors in human cholesteatoma. | 2003 | Laryngoscope | pmid:12616193 |
| Siggelkow H et al. | Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. | 2003 | J. Bone Miner. Res. | pmid:12619938 |
| Rude RK et al. | Magnesium deficiency: effect on bone and mineral metabolism in the mouse. | 2003 | Calcif. Tissue Int. | pmid:12370796 |
| Chen X et al. | Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. | 2003 | J. Nutr. Biochem. | pmid:12873716 |